Nestlé Picks Up Aimmune Therapeutics, Maker of Peanut Allergy Treatment
The No. 1 consumer goods company will acquire Aimmune Therapeutics, a biopharmaceutical company developing and commercializing treatments for food allergies, in a deal valued at $2.6 billion.